chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Recurrent back pain, painful joints, intestinal trouble, several headaches, pain in the chest, frequent trouble sleeping.  I'm in treatment in hospital.
Information has been received from a physician concerning an 15 year old female who on 30-MAY-1996 was vaccinated with a first dose of MMR II (route, site, dose and lot number not reported) HSA. On 02-APR-1998, the patient was vaccinated with a second dose of MMR II (route, site, dose and lot number not reported) HSA. On 30-NOV-2009, the patient experienced mumps (diagnosed date reported as 16-NOV-2009). The patient was afebrile and had parotitis. On 16-NOV-2009, the patient's lab results were serum IgM was negative, serum IgG was 8.99 and serum amylase was 112. The outcome of the mumps was not reported. Follow-up information was received from the physician reporting that the patient experienced mumps on 18-NOV-2009 (previously reported as 30-NOV-2010) and was diagnosed on 20-NOV-2009 (previously reported as 16-NOV-2009). The patient had right parotitis. On 20-NOV-2009, the patient's lab results were serum IgM was less than 1:10, serum IgG was 7.36 and serum amylase was 188. The outcome of the mumps were not reported. No further information is available.
low grade fever; experienced severe headache; sore arm; body aches; fatigue; This spontaneous case was reported by a nurse and describes the occurrence of PYREXIA (low grade fever), HEADACHE (experienced severe headache), PAIN IN EXTREMITY (sore arm), MYALGIA (body aches) and FATIGUE (fatigue) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 048A21A and 015M20A) for COVID-19 vaccination.     Concomitant products included SUMATRIPTAN for Migraine, ATORVASTATIN and FLUTICASONE PROPIONATE (FLONASE ALLERGY RELIEF) for an unknown indication.   On 09-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 11-Mar-2021, the patient experienced PYREXIA (low grade fever), HEADACHE (experienced severe headache), PAIN IN EXTREMITY (sore arm), MYALGIA (body aches) and FATIGUE (fatigue). At the time of the report, PYREXIA (low grade fever), HEADACHE (experienced severe headache), PAIN IN EXTREMITY (sore arm), MYALGIA (body aches) and FATIGUE (fatigue) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Patient had not experienced any adverse events after first dose. Treatment information were not provided.
On 9/24/13 pt was given FLUZONE HD. Pt came in 10/23/14 having pain in the site of administration. Pt advised to see MD and take MOTRIN.
About 24 hours after the administration of the vaccine, patient developed a rash that was warm to the touch on right deltoid, below the injection site. The rash spanned all the way down to just above the elbow. It did not span the circumference of the arm, it only appeared on the outside of the deltoid, below the injection site. The patient did not experience any hives or itching. Rash started to disappear early this week.
3/15: 10:00pm- severe chills and trembling, lasted six hours. 4:00am- vomiting, lasted two hours. Dizziness , fatigue and severe headache (ongoing). 3/16- severe tingling and numbness through right arm, right side and right leg. Right hand and right foot numb. Headache and nausea persisted. Dizziness and confusion. Example- need to walk through a door, can?t figure out that turning door handle is the solution.  3/17- tightness in chest and difficulty breathing (ongoing) can?t catch a deep breath(ongoing). Headache and fatigue persisting at this time.
Red, hot, itchy, swelling at injection site starting 7 days after dose one of vaccine.  Larger as the day went on (about the size of a grapefruit).  Feels hard to the touch. Had initial swelling first two days after vaccine, but then went away completely until today (day 7)
Severe proteinuria, hematuria, severe edema 3+ in bilateral legs and thighs
Nausea and repeated vomiting for 8 hours. Weak and in bed next day.  Temp of 102 degrees still at the end of the day. Just drank some liquid. Episode lasted 36 hours.  Lost 6 pounds.
The pt became very angry and negative immediately following the vaccines. He had sleepiness, low-grade fever and holding his head.
Vertigo episode on day 20 after a vaccine shot. I doubt symptoms were related to vaccine.
Hive like rash that started on feet and spread up both legs, stomach, chest, shoulders and arms; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0150) via an unspecified route of administration in the right arm on 01Apr2021 at 09:45 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Medical history included seasonal allergy. Concomitant medications included diphenhydramine hydrochloride (BENADRYL) from an unknown date for seasonal allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 03Apr2021 at 08:00, the patient experienced hive like rash that started on feet and had now spread up both legs, stomach, chest, shoulders and arms. Therapeutic measures were taken as a result of the events and included treatment with prednisone. The event resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of the event hive like rash that started on feet and has now spread up both legs, stomach, chest, shoulders and arms was not recovered.  No follow-up attempts are needed. No further information is expected.
14JAN97 830PM T104, crying, shallow breathing taken to ER, blood drawn, checked for pneumonia;rx APAP & motrin;saw family MD drew blood, fontanel raised;MD drew blood thinks infect;rx broad based ATB;MD does not think immun involved;
Abdominal pain; General weakness; Body aches; Headache; Feverishess; Dizziness; Chest tickling/ itchiness; Throat tickle; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (Dizziness), PRURITUS (Chest tickling/ itchiness), THROAT IRRITATION (Throat tickle), ABDOMINAL PAIN (Abdominal pain) and ASTHENIA (General weakness) in a 37-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 037CZ1A and 044BR1A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Anxiety on 02-Oct-2009 and Bipolar depression on 02-Oct-2009. Concurrent medical conditions included Allergy to chemicals (sensitivity to MSG (monosodium glutamate)). Concomitant products included ARIPIPRAZOLE (ABILIFY) from 15-Dec-2009 to an unknown date for Mood alteration NOS, SERTRALINE HYDROCHLORIDE (ZOLOFT) from 15-Dec-2009 to an unknown date and TAZAROTENE (TAZORAC) from 01-Jan-2021 to an unknown date for an unknown indication.   On 20-Apr-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 18-May-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 20-Apr-2021, the patient experienced PRURITUS (Chest tickling/ itchiness) and THROAT IRRITATION (Throat tickle). On 19-May-2021, the patient experienced DIZZINESS (Dizziness). On an unknown date, the patient experienced ABDOMINAL PAIN (Abdominal pain), ASTHENIA (General weakness), MYALGIA (Body aches), HEADACHE (Headache) and PYREXIA (Feverishess). At the time of the report, DIZZINESS (Dizziness), PRURITUS (Chest tickling/ itchiness), THROAT IRRITATION (Throat tickle), ABDOMINAL PAIN (Abdominal pain), ASTHENIA (General weakness), MYALGIA (Body aches), HEADACHE (Headache) and PYREXIA (Feverishess) outcome was unknown. Not Provided          Treatment medications was not reported. Action taken with mRNA-1273 in response to the events was not applicable.   This case was linked to MOD-2021-082924 (Patient Link).
Information has been received from a female patient referring to herself. The patient's current condition and medical history were not reported. On 18-MAR-2015 the patient was vaccinated with a dose of ZOSTAVAX (lot#, expiration date, dose and route were unknown). Concomitant therapies were not reported. On an unknown in March 2015 the patient had severe adverse event. The outcome of adverse event was unknown. Additional information is not expected as there was no patient's contact information.
Immediately after receipt of second shot I began experiencing night sweats and hot flashes. Within a month my period became irregular and as of February 2021 I have not had a period for 3 months.
got the worst flu of my life; Initial information received on 23-Nov-2020 regarding an unsolicited valid non-serious social media case  from a consumer (patient).  This case is linked to case 2020SA296074.  This case involves a patient of unknown demographics, who reported got the worst flu of my life (influenza), while he/she received vaccine influenza quadrival a-b multidose vaccine preserved (Fluzone).  The patient's medical history, medical treatments, vaccinations, condition medications and family history were not provided.  On an unknown date, the patient received influenza vaccine (batch number and expiry date unknown) via an unknown dose via unknown route at unknown administration site for prophylactic vaccination.  On an unknown date, (latency: unknown) after starting the suspect vaccine therapy, the patient stated got the worst flu of my life (influenza, that patient hot the shot since would be with kids. Now patient was older and had immune problems so patient definitely get it.  No lab data was reported.  It was not reported if the patient received any corrective treatment.  At the time of report, the event outcome was unknown for flu.  There will be no information available on the batch number for this case.
Scheduled for second COVID 19 dose. Pfizer Lot # EW0153 vial was reconstituted with .8 mL 0.9% sodium chloride instead of 1.8 mL. RN withdrew 0.3 mL diluent and administered IM to left deltoid. Pt remained for 15 minutes post injection. No adverse reactions noted. Patient reported headache, arm pain at injection site, low grade temp but pt did not assess temperature.  All symptoms were resolved within 24-48 hours.  No hospitalization required.
kind of sickness; Initial information was received on 30-Nov-2020 regarding an unsolicited valid non-serious case from a consumer (patient) via social media .  This case involves a patient (unknown demographics) who had kind of sickness (Illness), while received INFLUENZA VACCINE.  Medical history, past medical treatment, vaccination, family history and concomitant medications were not provided.  On an unknown date, the patient received an INFLUENZA VACCINE (Produced by unknown manufacturer) (lot number, expiry date and other dosing details were not reported) for prophylactic vaccination.  On an unknown date, patient had kind of sickness (Illness), (unknown latency), following the administration of INFLUENZA VACCINE..  Details of laboratory data not reported.  Corrective treatment and outcome were unknown at the time of reporting.  There will be no information available on the batch number for this case.
Mother called PHN and stated the morning after injection top lip and nose was swollen. After a couple of hours the swelling disappeared. There was no difficulty breathing or rash noted.
Information has been received from a physician concerning a 12 month old male who on 4/28/06 was vaccinated SC with a 0.5mL dose of MMR and varicella virus vaccine live. On approximately 4/28/06, shortly after the dosing, the patient developed a rash of about 5 to 10 lesions on the feet. Diphenhydramine hydrochloride was given. Unspecified medical attention was sought. There was no product quality complaint involved. The physician considered the event to be an other important medical event (OMIC). Additional information has been requested. There was no illness at the time of vaccination. On 09-MAY-2006. "shortly after the dosing", the patient developed a rash of about 5 to lesions on the feet. BENADRYL was given. Unspecified medical attention was sought. There was no product quality complaint involved. Follow up information indicated that on 09-MAY-2006, 11 days post vaccination, the patient was seen for fever to 101-102 degrees and a maculopapular rash. There were no relevant diagnostic tests or laboratory data. There were no adverse events following prior vaccinations. Additional information has been requested.
Vial was initially stored in the refrigerator on 30-JAN-2023, vaccine was administered on 02-MAR-2023; No adverse event; Patient had received a dose of the Moderna COVID-19 bivalent vaccine after a beyond use date of 01-MAR-2023; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient had received a dose of the Moderna COVID-19 bivalent vaccine after a beyond use date of 01-MAR-2023), PRODUCT STORAGE ERROR (Vial was initially stored in the refrigerator on 30-JAN-2023, vaccine was administered on 02-MAR-2023) and NO ADVERSE EVENT (No adverse event) in a 70-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 045H22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 02-Mar-2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) 1 dosage form. On 02-Mar-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient had received a dose of the Moderna COVID-19 bivalent vaccine after a beyond use date of 01-MAR-2023). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vial was initially stored in the refrigerator on 30-JAN-2023, vaccine was administered on 02-MAR-2023) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Patient had received a dose of the Moderna COVID-19 bivalent vaccine after a beyond use date of 01-MAR-2023), PRODUCT STORAGE ERROR (Vial was initially stored in the refrigerator on 30-JAN-2023, vaccine was administered on 02-MAR-2023) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Patient had received a dose of the Moderna COVID-19 bivalent vaccine after a beyond use date of 01-MAR-2023) and PRODUCT STORAGE ERROR (Vial was initially stored in the refrigerator on 30-JAN-2023, vaccine was administered on 02-MAR-2023).    No concomitant medications were reported. Patient did not report any adverse reactions Vial was initially stored in the refrigerator on 30-JAN-2023 and BUD was 01-MAR-2023. Vial did not undergo any temperature excursions. No treatment information was provided.   This case was linked to US-MODERNATX, INC.-MOD-2023-714608, US-MODERNATX, INC.-MOD-2023-714729, US-MODERNATX, INC.-MOD-2023-714789, US-MODERNATX, INC.-MOD-2023-714792 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-714608:Same reporter US-MODERNATX, INC.-MOD-2023-714729:Same reporter US-MODERNATX, INC.-MOD-2023-714789:Same reporter US-MODERNATX, INC.-MOD-2023-714792:Same reporter
02/07/22 presents to ED for "Light headedness" "fatigue". PMHx of "AAA, anemia, CKD, bladder cancer (stage unknown, diagnosed 7/2020 with recurrence in 2021 s/p radiation and current chemotherapy), CVA, and HTN
rash; This case was reported by a consumer via call center representative and described the occurrence of rash in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, less than 2 years after receiving Shingrix, the patient experienced rash. On an unknown date, the outcome of the rash was unknown.   It was unknown if the reporter considered the rash to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient stated that, developed rash after receiving dose of Shingrix. The patiet did not provide any further information and abruptly ended call.  No other information was available.
Painful lump in left armpit; administration date26Feb2021, administration date 15Mar2021; administration date 26Feb2021, administration date 15Mar2021; This is a spontaneous report from a contactable consumer (patient). A 42-year-old female patient (not pregnant) received bnt162b2 (COVID-19 vaccine), dose 2 via an unspecified route of administration, administered in Arm Left on 15Mar2021 09:45 AM (Batch/Lot number was not reported) at single dose for covid-19 immunisation. The patient' medical history was not reported, no allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. Concomitant medications within 2 weeks of vaccination included: Metformin, alprazolam (XANAX) and multivitamin. The patient didn't receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient previously received the first dose of bnt162b2 administered in Arm Left on 26Feb2021 09:00 AM for covid-19 immunization and experienced black nasal discharge. The patient experienced painful lump in left armpit since vaccines. It's been almost a month. Adverse event started from 15Mar2021 09:45 AM. No treatment was received for the event. Since the vaccination, the patient had not been tested for COVID-19. The outcome of the event was not recovered. The report was non-serious.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Acne looking rashes/bumps on all over body, especially both buttocks, legs and arms.
dizzy; terrible headache; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (dizzy) and HEADACHE (terrible headache) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1. On 09-Apr-2021, the patient experienced DIZZINESS (dizzy) and HEADACHE (terrible headache). At the time of the report, DIZZINESS (dizzy) and HEADACHE (terrible headache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.
Subject in pneumococcal vaccine trial, with severe COPD, was admitted to hospital with R collapsed lung (pneumothorax)Vaccination took place on 7/10/07and admission was on 7/20/2008. According to the physician, the relationship to treatment is 'None'. We would be happy to forward the Study's SAE Report Form upon request. Subject ID is A105080.
2/19/01 severe headache, temp, flu sx times 1 wk, tx for infection w/antibiotic, No resolution. Missed most of school between 2/19 to 3/01 MRI #1 R/O encephalitis, overnight hospitalization @ Emmanuel Legacy, Portland. 3/23-3/30/01 hospitalization @ hospital R/O migraines. No resolution from either hospitalization. Headaches progressively improved; still occurring but are not interfering with daily living. Rx: Zoloft 150mg currently decrease dose Depakote d/c 2 wks ago, Zanaflex d/c 1 wk ago.
flu-like symptoms, fever, and weakness for a few days after the vaccines; flu-like symptoms, fever, and weakness for a few days after the vaccines; flu-like symptoms, fever, and weakness for a few days after the vaccines; This spontaneous case was reported by a patient and describes the occurrence of INFLUENZA LIKE ILLNESS (flu-like symptoms, fever, and weakness for a few days after the vaccines), ASTHENIA (flu-like symptoms, fever, and weakness for a few days after the vaccines) and PYREXIA (flu-like symptoms, fever, and weakness for a few days after the vaccines) in an elderly male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch nos. 030G22B and AS7664B) for COVID-19 prophylaxis.     It was unknown if patient received any other vaccines in the 4 weeks prior to COVID-19 vaccine.    On 27-Oct-2022, the patient received fifth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 21-Aug-2023, received sixth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced INFLUENZA LIKE ILLNESS (flu-like symptoms, fever, and weakness for a few days after the vaccines), ASTHENIA (flu-like symptoms, fever, and weakness for a few days after the vaccines) and PYREXIA (flu-like symptoms, fever, and weakness for a few days after the vaccines). At the time of the report, INFLUENZA LIKE ILLNESS (flu-like symptoms, fever, and weakness for a few days after the vaccines), ASTHENIA (flu-like symptoms, fever, and weakness for a few days after the vaccines) and PYREXIA (flu-like symptoms, fever, and weakness for a few days after the vaccines) had resolved.            No concomitant medication was reported. Suspect product dosage text was reported as unknown. It was reported that patient had scheduled his Spikevax Vaccine for 21-Oct-2023 which will be exactly 2 months a good enough span or will it cause other symptoms besides what people normally get with vaccines. No treatment information was provided.   This case was linked to US-MODERNATX, INC.-MOD-2023-745569 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-745569:Same patient (Monovalent case)
Information has been received from a physician concerning a male patient who on an unspecified date was vaccinated with a dose of PNEUMOVAX 23. On an unspecified date the patient experienced high fever and was admitted in hospital after getting PNEUMOVAX 23. The patient sought unknown medical attention. The patient recovered on an unspecified date. Additional information has been requested.
No addtional AEs; CMA called to report administration of expired MMR II vaccine.; This spontaneous report was received from a medical assistant and refers to a 13-month-old female patient.  The patient's medical history, concurrent conditions, concomitant therapies and previous drugs reactions were not reported.  On 13-OCT-2022, the patient was vaccinated with an expired measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (rHA) (M-M-R II) at a dose of  0.5ml/once, first dose, lot #T033815, expiration date: 05-OCT-2022, administered for prophylaxis (route of administration was not provided). No additional adverse event were reported (Expired vaccine used).